Oura Files for IPO Seeking $16 Billion Valuation as Revenue Nearly Doubles

Oura has filed to go public, and the numbers in its S-1 make a compelling case for why investors have been circling this company.

Revenue for the nine months ended June 30 hit $1.2 billion, up from $697 million in the same period a year earlier. That is roughly a 72% jump, and it lands on top of a trajectory the company has been touting for months: $500 million in 2024 revenue, roughly $1 billion in 2025, and a projection of close to $2 billion for this year. Few consumer hardware companies scale that fast without stumbling. Oura, so far, hasn't.

The Finnish company, founded in 2013, is reportedly seeking to raise $3 billion in the offering. Bloomberg has previously reported a target valuation of $16 billion, a significant step up from the roughly $11 billion valuation it carried last October. That's a compressed timeline for a valuation gain of nearly 50%, and it puts real weight on the fundamentals disclosed in the filing.

Those fundamentals are, on their face, solid. Oura says it sold 3.6 million rings over the past year and now counts approximately 5 million paid members, users who pay for the subscription tier that unlocks deeper health metrics. Retention is the number that should catch a portfolio manager's eye: an 85% weighted-average 12-month membership retention rate. In subscription businesses, that figure is often the difference between a durable franchise and a fad. An 85% retention rate suggests Oura has built something closer to the former, at least so far.

The Subscription Engine and Its Risks

The core product is a ring, priced between $350 and $400, that tracks metabolism, heart rate, stress, and sleep patterns. But the ring itself isn't really the business. The recurring subscription revenue is. Oura markets the combined hardware-software package as an "always-on health intelligence platform," and the company's S-1 leans hard into where that platform can go next.

Oura's filing states plainly that it sees its addressable market extending well past fitness tracking. The company wants to build clinical evidence, deepen integrations with health plans, employers, and care providers, and expand access to populations beyond the quantified-self crowd that adopted wearables early. It's also betting on data as a moat. The filing claims Oura has amassed one of the largest longitudinal biometric datasets in consumer health, tracking more than 50 metrics across nearly 42 billion hours of physiological data. That dataset, the company says, powers AI and machine-learning models that improve in accuracy and predictive capability as member histories deepen.

That's the pitch. The AI overlay isn't just for the top of the sales funnel. It's the thing making the retention number possible.

But there's a legal cloud hanging over the growth story. Oura was recently hit with a proposed class action lawsuit alleging the company misled users about the accuracy of its sleep tracking. The complaint claims the ring can't detect the physiological signals needed to determine actual sleep stages and instead relies on AI-generated estimates the suit compares, unflatteringly, to a coin flip. That allegation follows years of online grumbling from users who felt Oura consistently rated their sleep as optimal when it plainly wasn't. Oura disputes the claims and says it will defend itself in the appropriate legal forum, but the timing, right as the company pitches public investors on the reliability of its "health intelligence platform," is not ideal.

Competition is also intensifying, and not just from established rivals. Circular, another smart ring maker, just unveiled its Ring 3 series with FDA-cleared ECG for AFib detection, blood pressure trend tracking, and glucose tracking, features that push into more clinically rigorous territory. RingConn's Gen 3 and Oura's own Ring 5 have both launched within the past year. The smart ring category, once a niche occupied almost entirely by Oura, is now genuinely crowded. Pricing power and feature differentiation will matter more, not less, as public-market scrutiny increases.

None of this means the IPO thesis collapses. Retention at 85% is a real signal of product-market fit, and a near-doubling of revenue in twelve months is not something companies fake in an S-1. The dataset claim, if true and defensible, could be a genuine moat against hardware-only competitors racing to add sensors. But investors should separate the narrative Oura is selling, that of a healthcare platform poised to expand into clinical partnerships and insurance integrations, from what the company currently is: a wearables business generating most of its revenue from consumer subscriptions, facing active litigation over the core accuracy claims underpinning that subscription value.

What Investors Should Watch

Three things will determine whether Oura's public debut lives up to the $16 billion price tag. First, watch how the lawsuit progresses and whether discovery surfaces evidence that materially undercuts Oura's sleep-tracking claims; a negative outcome there strikes directly at the retention and trust metrics the company is leaning on. Second, watch gross margin trends as competition from Circular, RingConn, and others potentially forces price concessions on hardware. Third, and most important for the long-term valuation, watch whether Oura actually lands health plan, employer, and care provider partnerships at scale, or whether that language in the S-1 remains aspirational. A $16 billion valuation prices in a platform business. The filing, so far, describes a very good wearables company with platform ambitions. The gap between those two things is where this IPO will be won or lost.